ArticleJournal for immunotherapy of cancer2026

Pharmacokinetic variability with pembrolizumab dosage switching and its impact on immune-related adverse events in patients with non-small cell lung cancer.

Ryoko Inaba Higashiyama et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.